Consultation on Draft Guidance Document: Regulatory Requirements for Drug Identification Numbers (DINS)
Current status: Closed
Opened on January 25, 2019 and will close to new input on February 25, 2019.
The purpose of this consultation is to seek feedback from stakeholders on the Draft Guidance Document: Regulatory Requirements for Drug Identification Numbers (DINs). This document is intended to consolidate currently published information to improve accessibility of information and understanding of regulatory requirements for industry.
Join in: how to participate
Send an email to hc.DIN.email@example.com with your ideas or comments to make yourself heard.
Who is the focus of this consultation
We will engage with:
- Industry stakeholders, including: Disinfectants, Generic Drugs, Innovators / Biologic Drugs, Over-the-Counter (Non-prescription Drugs), Radiopharmaceutical Drugs and Veterinary Drugs
- Interested members of the public and consumers
Key questions for discussion
Your ideas and inputs are sought around the following themes/topics:
- What are your thoughts on the consolidation of information into one guidance document?
- What other information on the processes would be valuable from industry's point of view? Please identify specific areas that could be better covered.
The input gathered through this process will be used to publish a final guidance document for implementation.
Via email: HC.DIN.SC@canada.ca
Report a problem or mistake on this page
- Date modified: